Intravenous Esketamine on Prevention of Postoperative Depression in Patients Undergoing Cardiac Surgery

• Status: Recruiting
• Trial end date: 2022-12-15
• Target enrollment: 0
• Participant gender: All

Summary

Esketamine is a general anesthetic with anti-depressant effects at subanaesthetic doses. This study hypothesized that intraoperative administration of ketamine would prevent or mitigate postoperative depressive symptoms in surgical patients.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Anshi Wu
• Treatments: Esketamine; Ketamine

Criteria

Inclusion Criteria:

• 1:Patients scheduled for heart surgery

• 2:Moderate to severe depressive symptom measured by the qualified psychiatric doctors

• 3:Over 18 years of age

• 4:American Society of Anesthesiologists physical status I-III

Exclusion Criteria:

• 1:History of epilepsy

• 2:Major depression disorder patients undergoing antidepressive therapy within 2 weeks

• 3: Psychiatric illness

• 4: Drug abuse

• 5:History of allergy to esketamine

• 6:Hyperthyroidism

• 7:Patients can not cooperate with investigators on psychiatric assessments

• 8:Pregnant or breastfeeding woman

• 9:refuse to sign informed consent.